Clinical Studies
Browse by
Recent submissions
-
Searching for treatments for non-G12C-KRAS mutant cancers.
(2021-04-15)KRAS mutations drive a wide variety of cancers. Drugs targeting the protein product of KRAS<sup>G12C</sup> mutations are currently being evaluated show preliminary efficacy in clinical trials. A clinical trial of VS-6766, ... -
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
(2021-04-16)Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies ... -
Monitoring advances including consent: learning from COVID-19 trials and other trials running in UKCRC registered clinical trials units during the pandemic
<jats:title>Abstract</jats:title><jats:p>The COVID-19 pandemic has affected how clinical trials are managed, both within existing portfolios and for the rapidly developed COVID-19 trials. Sponsors or delegated organisations ... -
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease.
(2021-03-19)<h4>Background</h4>In the CARD study (NCT02485691), cabazitaxel significantly improved clinical outcomes versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated ... -
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors.
(2020-09-28)Targeting the ataxia telangiectasia and RAD3-related (ATR) enzyme represents a promising anticancer strategy for tumors with DNA damage response (DDR) defects and replication stress, including inactivation of ataxia ... -
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
(2021-01-19)Prostate cancer is one of the most frequent cancers in men and is a common cause of cancer-related death. Despite significant progress in the diagnosis and treatment of this tumor, patients who relapse after radical ... -
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome Sequencing.
(2021-01-09)1.<h4>Background</h4>The application of massively parallel sequencing has led to the identification of aberrant druggable pathways and somatic mutations within therapeutically relevant genes in gastro-oesophageal cancer. ... -
Lights and Shadows in Immuno-Oncology Drug Development.
(2021-02-09)The rapidly evolving landscape of immuno-oncology (IO) is redefining the treatment of a number of cancer types. IO treatments are becoming increasingly complex, with different types of drugs emerging beyond checkpoint ... -
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies.
(2021-02-04)<h4>Purpose</h4>Although enzalutamide (ENZ) has been widely used to treat <i>de novo</i> or castration-resistant metastatic prostate cancer, resistance develops and disease progression is ultimately inevitable. There are ... -
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer
(AMER ASSOC CANCER RESEARCH, 2021-02-15) -
3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer.
(2021-01-28)Triple-negative breast cancers (TNBC) are resistant to standard-of-care chemotherapy and lack known targetable driver gene alterations. Identification of novel drivers could aid the discovery of new treatment strategies ... -
CD38 in Advanced Prostate Cancers.
<h4>Background</h4>CD38, a druggable ectoenzyme, is involved in the generation of adenosine, which is implicated in tumour immune evasion. Its expression and role in prostate tumour-infiltrating immune cells (TIICs) have ... -
Targeting the PD-1/PD-L1 axis in non-small cell lung cancer.
The last decade has witnessed rapid advances in the discovery and development of immune checkpoint inhibitors in cancer medicine, particularly drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand ... -
Developing biomarker-driven treatments for oesophagogastric cancer
(2020-08-31)Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ... -
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
BACKGROUND:The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate ... -
A prospective observational study of on-treatment plasma homocysteine levels as a biomarker of toxicity, depression and vitamin supplementation lead-in time pre pemetrexed, in patients with non-small cell lung cancer and malignant mesothelioma.
<h4>Objectives</h4>Vitamin supplementation reduces pemetrexed toxicity. Raised plasma homocysteine reflects deficiency in vitamin B12 and folate, and is suppressed by supplementation. This observational study of 112 patients ... -
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.
(2021-01-11)Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research ... -
SARS-CoV-2 vaccination and phase 1 cancer clinical trials.
(2021-02-08)
RSS 1.0